TABLE 1.
Characteristics of AASK participants at 5 starting thresholds
| eGFR 30 ml/min/1.73 m2 |
eGFR 15 ml/min/1.73 m2 |
5% ESRD risk | 10% ESRD risk |
20% ESRD risk | |
|---|---|---|---|---|---|
| No. of participants | 566 | 244 | 437 | 336 | 259 |
| Time from randomization (mo) | 25 [0–67] | 50 [27–88] | 26 [0–65] | 37 [8–73] | 45 [20–80] |
| Age (y) | 56.3 ±11.9 | 55.1 ±11.2 | 53.9 ±11.7 | 53.9 ±12.0 | 53.9 ±11.6 |
| Male sex | 325 (57.4) | 125 (51.2) | 260 (59.5) | 197 (58.6) | 141 (54.4) |
| eGFR (ml/min/1.73 m2) | 26 [24–29] | 13 [11–14] | 26 [22–29] | 22 [18–24] | 16 [13–18] |
| BMI (kg/m2) | 31.1 ±7.6 | 31.8 ±7.4 | 31.8 ±7.9 | 32.0 ±7.9 | 32.3 ±7.9 |
| Systolic blood pressure (mmHg) | 138.4 (23.4) | 137.8 (21.5) | 142.8 (23.2) | 143.5 (22.3) | 140.2 (21.7) |
| Diastolic blood pressure (mmHg) | 84.1 (16.7) | 81.0 (13.5) | 86.7 (16.3) | 86.7 (15.9) | 83.6 (14.7) |
| Hematocrit (g/dL) | 37.0 (5.1) | 33.4 (5.0) | 36.9 (5.3) | 36.2 (5.1) | 34.6 (5.4) |
| Urine ACR (mg/g)*** | 179 [38–541] | 641 [229–1131] | 457 [231–770] | 633 [345–948] | 854 [551–1242] |
| Urine PCR >1 g/g*** | 164 (30.0) | 148 (64.3) | 213 (48.7) | 219 (65.2) | 200 (77.2) |
| APOL1 high-risk status* | 117 (30.2) | 56 (32.4) | 96 (31.8) | 80 (34.3) | 63 (35.4) |
| Antecedent eGFR slope** (ml/min/1.73 m2 per y) | −2.7 (20.8) | −6.0 (7.8) | −3.3 (10.4) | −3.9 (9.1) | −5.6 (10.3) |
| Rapid eGFR progression** | 133 (35.3) | 134 (55.6) | 104 (36.2) | 101 (38.6) | 118 (49.6) |
| Follow-up to ESRD or death (mo) | 44 [25–83] | 9 [4–19] | 35 [18–55] | 23 [12–39] | 13 [6–24] |
| Proportion reaching outcome | |||||
| Administrative censoring | 190 (33.6) | 30 (12.3) | 103 (23.6) | 47 (14.0) | 29 (11.2) |
| Death before ESRD | 80 (14.1) | 12 (4.9) | 46 (10.5) | 28 (8.3) | 12 (4.6) |
| ESRD | 296 (52.3) | 202 (82.8) | 288 (65.9) | 261 (77.7) | 218 (84.2) |
ACR, albumin-creatinine ratio; BMI, body mass index; PCR, protein-creatinine ratio; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease;
Note: Kidney failure risk equation uses age, sex, urine ACR, and eGFR to estimate 1-year risk of ESRD. Values for categorical variables represent number (percentage) and values for continuous variables represent mean ± standard deviation or median [interquartile range] during the first study visit at which the participant had eGFR <30 ml/min/1.73 m2, eGFR <15 ml/min/1.73 m2, or 1-year ESRD risk >5%, >10%, or >20%. ACR was estimated from PCR using a linear conversion factor separately for men and women. Antecedent eGFR slope was calculated from all eGFR values measured in study visits during the preceding 3 years. Rapid eGFR progression was defined as an antecedent eGFR slope of lesser magnitude than −5 ml/min/1.73 m2 per year.
Genotype data available for 388, 173, 302, 233, and 178 participants with eGFR <30 ml/min/1.73 m2, eGFR <15 ml/min/1.73 m2, and 1-y ESRD risks of >5%, >10%, and >20%, respectively.
eGFR slope available for 377, 241, 287, 262, and 238 participants with eGFR <30 ml/min/1.73m2, eGFR <15 ml/min/1.73m2, 1-year ESRD risk >5%, 1-year ESRD risk >10%, and 1-year ESRD risk >20%, respectively. Follow-up to ESRD or death was estimated using Kaplan-Meier methods.
PCR available for 546 and 230 participants with eGFR <30 ml/min/1.73m2 and eGFR <15 ml/min/1.73m2, respectively.